Summary
The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy.
Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026).
Several companies, such as Pfizer (PF-07976016), Regor Therapeutics (RGT-075), AstraZeneca (AZD5004), and others, are also evaluating their oral GLP-1 candidates to give competition to Novo and Eli Lilly.
The era of needle-only obesity treatment is officially over. After years of blockbuster injectable drugs dominating headlines, and medicine cabinets, the obesity pharmacotherap...
